

REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE COMMUNITY
--

To be filled in by the applicant

The questions in this form for the request for authorisation from the Competent Authority are also relevant for the opinion from an Ethics Committee (it represents module 1 of the form for applying to an ethics committee) and can be used as part of that application. Please indicate the relevant purpose in a box below.

REQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY: Yes ●
REQUEST FOR OPINION OF THE ETHICS COMMITTEE: No ●

A. TRIAL IDENTIFICATION

A.1	Member State in which the submission is being made:	Denmark - DHMA
A.2	EudraCT number:	2018-000404-42
A.3	Full title of the trial: English	The Conservative vs. Liberal Approach to fluid therapy of Septic Shock in Intensive Care Trial
A.3.1	Title of the trial for lay people, in easily understood, i.e. non-technical, language: English	The Conservative vs. Liberal Approach to fluid therapy of Septic Shock in Intensive Care Trial
A.3.2	Name or abbreviated title of the trial where available: English	CLASSIC
A.4	Sponsor's protocol code number, version and date ¹ :	
A.4.1	Sponsor's protocol code number:	RH-ITA-007
A.4.2	Sponsor's protocol version:	2.3
A.4.3	Sponsor's protocol date:	2019-06-19
A.5	Additional international study identifiers (e.g. WHO, ISRCTN ² , US NCT Number ³) if available	
A.5.1	ISRCTN number:	
A.5.2	US NCT number:	
A.5.3	WHO Universal Trial Number (UTN):	
A.5.4	Other Identifier:	
A.6	Is this a resubmission?	No ●
	If 'Yes', indicate the resubmission letter ⁴ :	First Submission
A.7	Is the trial part of an agreed Paediatric Investigation Plan?	No ●
A.8	EMA Decision number of Paediatric Investigation Plan:	

B. IDENTIFICATION OF THE SPONSOR RESPONSIBLE FOR THE REQUEST

B.1 SPONSOR		
B.1.1	Name of organisation:	Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet
B.1.2	Name of the person to contact:	
B.1.2.1	Given name	Anders
B.1.2.2	Middle name	
B.1.2.3	Family name	Perner
B.1.3	Address:	
B.1.3.1	Street address	Blegdamsvej 9
B.1.3.2	Town/city	Copenhagen
B.1.3.3	Post code	2100
B.1.3.4	Country	Denmark
B.1.4	Telephone number:	0045 35458333
B.1.5	Fax number:	Danma 24 224956
B.1.6	E-mail:	anders.perner@regionh.dk
B.2 LEGAL REPRESENTATIVE⁵ OF THE SPONSOR IN THE COMMUNITY FOR THE PURPOSE OF THIS TRIAL (if different from the sponsor)		
B.2.1	Name of organisation:	
B.2.2	Name of person to contact:	
B.2.2.1	Given name	
B.2.2.2	Middle name	
B.2.2.3	Family name	
B.2.3	Address:	
B.2.3.1	Street address	
B.2.3.2	Town/city	
B.2.3.3	Post code	
B.2.3.4	Country	
B.2.4	Telephone number:	
B.2.5	Fax number:	
B.2.6	E-mail:	
B.3 STATUS OF THE SPONSOR:		
B.3.1	Commercial:	No •
B.3.2	Non commercial:	Yes •
B.4 Source(s) of Monetary or Material Support for the clinical trial (repeat as necessary):		
B.4.1	Name of organisation:	The Novo Nordisk Foundation
B.4.2	Country:	Denmark
B.5 Contact point⁶ designated by the sponsor for further information on the trial		
B.5.1	Name of organisation:	Dept. of Intensive Care Rigshospitalet
B.5.2	Functional name of contact point (e.g. "Clinical Trial Information Desk"):	Clinical Trials Information
B.5.3	Address:	
B.5.3.1	Street address	Blegdamsvej 9
B.5.3.2	Town/city	Copenhagen
B.5.3.3	Post code	2100
B.5.3.4	Country	Denmark
B.5.4	Telephone number:	
B.5.5	Fax number:	
B.5.6	E-mail: (use a functional e-mail address rather than a personal one)	anders.perner@regionh.dk

C. APPLICANT IDENTIFICATION, (please tick the appropriate box)

C.1 REQUEST FOR THE COMPETENT AUTHORITY	
C.1.1	Sponsor
C.1.2	Legal representative of the sponsor
C.1.3	Person or organisation authorised by the sponsor to make the application Yes •
C.1.4	Complete the details of the applicant below even if they are provided elsewhere on the form:
C.1.4.1	Name of Organisation: Dept. of Intensive Care Rigshospitalet
C.1.4.2	Name of contact person:
C.1.4.2.1	Given name Tine
C.1.4.2.2	Middle name Sylvest
C.1.4.2.3	Family name Meyhoff
C.1.4.3	Address:
C.1.4.3.1	Street address Blegdamsvej 9
C.1.4.3.2	Town/city Copenhagen
C.1.4.3.3	Post code 2100
C.1.4.3.4	Country Denmark
C.1.4.4	Telephone number:
C.1.4.5	Fax number:
C.1.4.6	E-mail: tine.sylvest.meyhoff@regionh.dk
C.1.5	Request to receive a copy of CTA data as XML:
C.1.5.1	Do you want a copy of the CTA form data saved on EudraCT as an XML file? Yes •
C.1.5.1.1	If Yes provide the e-mail address(es) to which it should be sent (up to 5 addresses): tine.sylvest.meyhoff@regionh.dk
C.1.5.1.2	Do you want to receive this via password protected link(s)?? No •
If you answer No to question C.1.5.1.2 the .xml file will be transmitted by less secure e-mail link(s)	

D. INFORMATION ON EACH IMP

Information on each 'bulk product' before trial-specific operations (blinding, trial specific packaging and labelling) should be provided in this section for each investigational medicinal product (IMP) being tested including each comparator and each placebo, if applicable. **For placebo go directly to D.8.** If the trial is performed with several products use extra pages and give each product a sequential number in D.1.1. If the product is a combination product, information should be given for each active substance.

D.1 IMP IDENTIFICATION		
Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial (assign numbers from 1-n):		
D.1.1	This refers to the IMP number:	PR1
D.1.2	IMP being tested	Yes •
D.1.3	IMP used as a comparator	No •
D.2 STATUS OF THE IMP		
D.2.1	Has the IMP to be used in the trial a marketing authorisation? Yes • If the IMP has a marketing authorisation in the Member State concerned by this application, but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2.	
D.2.1.1	If 'Yes', specify the product to be used in the clinical trial:	
D.2.1.1.1	Trade name	
D.2.1.1.1.1	EV Product Code (where applicable)	
D.2.1.1.2	Name of the Marketing Authorisation Holder:	
D.2.1.1.3	Marketing Authorisation number (if Marketing Authorisation granted by a Member State):	
D.2.1.1.4	Is the IMP modified in relation to its Marketing Authorisation? No •	
D.2.1.1.4.1	If 'Yes', please specify:	
D.2.1.2	The country that granted the Marketing Authorisation	Denmark
D.2.1.2.1	Is this the Member State concerned with this application?	Yes •
D.2.2	Situations where an IMP to be used in the CT has a Marketing Authorisation in the Member State concerned, but the protocol allows that any brand of the IMP with a Marketing Authorisation in that Member State be administered to the trial subjects and it is not possible to clearly identify the IMP(s) in advance of the trial start	
D.2.2.1	In the protocol, is treatment defined only by active substance?	No •
D.2.2.1.1	If 'Yes', give active substance in D.3.8 or D.3.9	
D.2.2.2	In the protocol, do treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS?	No •
D.2.2.2.1	If 'Yes', give active substance in D.3.8 or D.3.9	
D.2.2.3	The products to be administered as IMPs are defined as belonging to an ATC group ⁹	Yes •
D.2.2.3.1	If 'Yes', give the ATC group of the applicable authorised codes in the ATC code field (level 3 or the level that can be defined) in D.3.3	
D.2.2.4	Other:	No •
D.2.2.4.1	If 'Yes', please specify:	
D.2.3	IMPD submitted:	
D.2.3.1	Full IMPD:	No •
D.2.3.2	Simplified IMPD:	No •
D.2.3.3	Summary of product characteristics (SmPC) only:	Yes •
D.2.4	Has the use of the IMP been previously authorised in a	Yes •

D.2.4.1	clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States:	Denmark Finland
D.2.5	Has the IMP been designated in this indication as an orphan drug in the Community?	No •
D.2.5.1	If 'Yes', give the orphan drug designation number ¹⁰ :	

D.2.6	Has the IMP been the subject of scientific advice related to this clinical trial?	No •
D.2.6.1	If 'Yes' to D.2.6, please indicate source of advice and provide a copy in the CTA request:	
D.2.6.1.1	CHMP ¹¹ ?	No •
D.2.6.1.2	National Competent Authority?	No •

D.3	DESCRIPTION OF THE IMP	
D.3.1	Product name where applicable ¹² :	
D.3.2	Product code where applicable ¹³ :	
D.3.3	ATC codes, if officially registered ¹⁴ :	B05BB01
D.3.4	Pharmaceutical form (use standard terms):	Solution for infusion
D.3.4.1	Is this a specific paediatric formulation?	No •
D.3.5	Maximum duration of treatment of a subject according to the protocol:	
D.3.6	Dose allowed:	
D.3.6.1	For first trial only: Specify per day or total Specify total dose (number and unit): Route of administration (relevant to the first dose):	Total •
D.3.6.2	For all trials Specify per day or total Specify total dose (number and unit): Route of administration (relevant to the maximum dose):	Total • Intravenous use
D.3.7	Routes of administration (use standard terms):	Intravenous use

D.3.8	Name of each active substance (INN or proposed INN if available):	
	Sodium Chloride	
D.3.9	Other available name for each active substance (provide all available):	
D.3.9.1	CAS ¹⁵ number	
D.3.9.2	Current sponsor code	
D.3.9.3	Other descriptive name	
	SODIUM CHLORIDE SOLUTION 0.9%	
D.3.9.4	EV Substance code	SUB20079
D.3.9.5	Full Molecular formula	
D.3.9.6	Chemical/biological description of the Active Substance	
D.3.10	Strength (specify all strengths to be used):	
D.3.10.1	Concentration unit:	
D.3.10.2	Concentration type ("exact number", "range", "more than" or "up to"):	
D.3.10.3	Concentration (number).	

D.3.11	Type of IMP	
	Does the IMP contain an active substance:	
D.3.11.1	Of chemical origin?	Yes •
D.3.11.2	Of biological / biotechnological origin (other than Advanced Therapy IMP (ATIMP))?	No •
	Is this a:	

D.3.11.3	Advanced Therapy IMP (ATIMP)?	No ●
D.3.11.3.1	Somatic cell therapy medicinal product ¹⁶ ?	No ●
D.3.11.3.2	Gene therapy medicinal product ¹⁷ ?	No ●
D.3.11.3.3	Tissue Engineered Product ¹⁸ ?	No ●
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device ¹⁹)?	No ●
D.3.11.3.5	Has the Committee on Advanced Therapies issued a classification for this product?	No ●
D.3.11.3.5.1	If 'Yes' please provide that classification and its reference number:	
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy?	No ●
D.3.11.5	Radiopharmaceutical medicinal product?	No ●
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)?	No ●
D.3.11.7	Plasma derived medicinal product?	No ●
D.3.11.8	Extractive medicinal product?	No ●
D.3.11.9	Recombinant medicinal product?	No ●
D.3.11.10	Medicinal product containing genetically modified organisms?	No ●
D.3.11.10.1	Has the authorisation for contained use or release been granted?	No ●
D.3.11.10.2	Is it pending?	No ●
D.3.11.11	Herbal medicinal product?	No ●
D.3.11.12	Homeopathic medicinal product?	No ●
D.3.11.13	Another type of medicinal product?	No ●
D.3.11.13.1	If 'another type of medicinal product' specify the type of medicinal product:	
D.3.12	Mode of action (<i>free text</i> ²⁰)	
D.3.13	Is it an IMP to be used in a first-in-human clinical trial?	No ●
D.3.13.1	If 'Yes', are there risk factors identified, according to the guidance FIH? ²¹	

D.4	SOMATIC CELL THERAPY INVESTIGATIONAL MEDICINAL PRODUCT (NO GENETIC MODIFICATION)	
D.4.1	Origin of cells	
D.4.1.1	Autologous	No ●
D.4.1.2	Allogeneic	No ●
D.4.1.3	Xenogeneic	No ●
D.4.1.3.1	If 'Yes', specify the species of origin:	
D.4.2	Type of cells	
D.4.2.1	Stem cells	No ●
D.4.2.2	Differentiated cells	No ●
D.4.2.2.1	If 'Yes', specify the type (e.g. keratinocytes, fibroblasts, chondrocytes...):	
D.4.2.3	Others:	No ●
D.4.2.3.1	If others, specify:	

D.5	GENE THERAPY INVESTIGATIONAL MEDICINAL PRODUCTS	
D.5.1	Gene(s) of interest:	
D.5.2	In vivo gene therapy:	No ●
D.5.3	Ex vivo gene therapy:	No ●
D.5.4	Type of gene transfer product	
D.5.4.1	Nucleic acid (e.g. plasmid):	No ●
	If 'Yes', specify if:	
D.5.4.1.1	Naked:	No ●
D.5.4.1.2	Complexed	No ●

D.5.4.2	Viral vector:	No •
D.5.4.2.1	If 'Yes', specify the type: adenovirus, retrovirus, AAV, ...:	
D.5.4.3	Others	No •
D.5.4.3.1	If others, specify:	
D.5.5	Genetically modified somatic cells:	No •
	If 'Yes', specify the origin of the cells:	
D.5.5.1	Autologous:	No •
D.5.5.2	Allogeneic:	No •
D.5.5.3	Xenogeneic:	No •
D.5.5.3.1	If 'Yes', specify the species of origin:	
D.5.5.4	Specify type of cells (hematopoietic stem cells...):	

D.6 TISSUE ENGINEERED PRODUCT		
The indication which determines that this is a Tissue Engineered Product as opposed to a Cell Therapy product is given in section E.1.1.		
D.6.1	Origin of cells	
D.6.1.1	Autologous	No •
D.6.1.2	Allogeneic	No •
D.6.1.3	Xenogeneic	No •
D.6.1.3.1	If 'Yes', specify the species of origin:	
D.6.2	Type of cells	
D.6.2.1	Stem cells	No •
D.6.2.2	Differentiated cells	No •
D.6.2.2.1	If 'Yes', specify the type of cells(e.g. keratinocytes, fibroblasts, chondrocytes, ...):	
D.6.2.3	Others:	No •
D.6.2.3.1	If others, specify:	

D.7 PRODUCTS CONTAINING DEVICES (i.e. MEDICAL DEVICES, SCAFFOLDS ETC.)		
D.7.1	Give a brief description of the device:	
D.7.2	What is the name of the device?	
D.7.3	Is the device implantable?	No •
D.7.4	Does this product contain:	
D.7.4.1	A medical device?	No •
D.7.4.1.1	Does this medical device have a CE mark?	No •
D.7.4.1.1.1	The notified body is:	
D.7.4.2	Bio-materials?	No •
D.7.4.3	Scaffolds?	No •
D.7.4.4	Matrices?	No •
D.7.4.5	Other?	No •
D.7.4.5.1	If other, specify:	

D.1 IMP IDENTIFICATION		
Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial (assign numbers from 1-n):		
D.1.1	This refers to the IMP number:	PR2
D.1.2	IMP being tested	Yes •
D.1.3	IMP used as a comparator	No •

D.2 STATUS OF THE IMP		
------------------------------	--	--

D.2.1	Has the IMP to be used in the trial a marketing authorisation? Yes • If the IMP has a marketing authorisation in the Member State concerned by this application, but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2.
D.2.1.1	If 'Yes', specify the product to be used in the clinical trial:
D.2.1.1.1	Trade name
D.2.1.1.1.1	EV Product Code (where applicable)
D.2.1.1.2	Name of the Marketing Authorisation Holder:
D.2.1.1.3	Marketing Authorisation number (if Marketing Authorisation granted by a Member State):
D.2.1.1.4	Is the IMP modified in relation to its Marketing Authorisation? No •
D.2.1.1.4.1	If 'Yes', please specify:
D.2.1.2	The country that granted the Marketing Authorisation Denmark
D.2.1.2.1	Is this the Member State concerned with this application? Yes •

D.2.2	Situations where an IMP to be used in the CT has a Marketing Authorisation in the Member State concerned, but the protocol allows that any brand of the IMP with a Marketing Authorisation in that Member State be administered to the trial subjects and it is not possible to clearly identify the IMP(s) in advance of the trial start
D.2.2.1	In the protocol, is treatment defined only by active substance? No •
D.2.2.1.1	If 'Yes', give active substance in D.3.8 or D.3.9
D.2.2.2	In the protocol, do treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS? No •
D.2.2.2.1	If 'Yes', give active substance in D.3.8 or D.3.9
D.2.2.3	The products to be administered as IMPs are defined as belonging to an ATC group ⁹ Yes •
D.2.2.3.1	If 'Yes', give the ATC group of the applicable authorised codes in the ATC code field (level 3 or the level that can be defined) in D.3.3
D.2.2.4	Other: No •
D.2.2.4.1	If 'Yes', please specify:

D.2.3	IMPD submitted:
D.2.3.1	Full IMPD: No •
D.2.3.2	Simplified IMPD: No •
D.2.3.3	Summary of product characteristics (SmPC) only: Yes •
D.2.4	Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? Yes •
D.2.4.1	If 'Yes' specify which Member States: Denmark Finland
D.2.5	Has the IMP been designated in this indication as an orphan drug in the Community? No •
D.2.5.1	If 'Yes', give the orphan drug designation number ¹⁰ :

D.2.6	Has the IMP been the subject of scientific advice related to this clinical trial? No •
D.2.6.1	If 'Yes' to D.2.6, please indicate source of advice and provide a copy in the CTA request:
D.2.6.1.1	CHMP ¹¹ ? No •
D.2.6.1.2	National Competent Authority? No •

D.3	DESCRIPTION OF THE IMP
D.3.1	Product name where applicable ¹² :
D.3.2	Product code where applicable ¹³ :

D.3.3	ATC codes, if officially registered ¹⁴ :	B05BB01
D.3.4	Pharmaceutical form (use standard terms):	Solution for infusion
D.3.4.1	Is this a specific paediatric formulation?	No •
D.3.5	Maximum duration of treatment of a subject according to the protocol:	
D.3.6	Dose allowed:	
D.3.6.1	For first trial only: Specify per day or total	Total •
	Specify total dose (number and unit): Route of administration (relevant to the first dose):	
D.3.6.2	For all trials Specify per day or total	Total •
	Specify total dose (number and unit): Route of administration (relevant to the maximum dose):	Intravenous use
D.3.7	Routes of administration (use standard terms):	Intravenous use

D.3.8	Name of each active substance (INN or proposed INN if available): Ringers Acetate	
D.3.9	Other available name for each active substance (provide all available):	
D.3.9.1	CAS ¹⁵ number	
D.3.9.2	Current sponsor code	
D.3.9.3	Other descriptive name RINGER'S ACETATE SOLUTION	
D.3.9.4	EV Substance code	SUB190935
D.3.9.5	Full Molecular formula	
D.3.9.6	Chemical/biological description of the Active Substance	
D.3.10	Strength (specify all strengths to be used):	
D.3.10.1	Concentration unit:	
D.3.10.2	Concentration type ("exact number", "range", "more than" or "up to"):	
D.3.10.3	Concentration (number).	

D.3.11	Type of IMP	
Does the IMP contain an active substance:		
D.3.11.1	Of chemical origin?	Yes •
D.3.11.2	Of biological / biotechnological origin (other than Advanced Therapy IMP (ATIMP))?	No •
Is this a:		
D.3.11.3	Advanced Therapy IMP (ATIMP)?	No •
D.3.11.3.1	Somatic cell therapy medicinal product ¹⁶ ?	No •
D.3.11.3.2	Gene therapy medicinal product ¹⁷ ?	No •
D.3.11.3.3	Tissue Engineered Product ¹⁸ ?	No •
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device ¹⁹)?	No •
D.3.11.3.5	Has the Committee on Advanced Therapies issued a classification for this product?	No •
D.3.11.3.5.1	If 'Yes' please provide that classification and its reference number:	
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy?	No •
D.3.11.5	Radiopharmaceutical medicinal product?	No •
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)?	No •
D.3.11.7	Plasma derived medicinal product?	No •
D.3.11.8	Extractive medicinal product?	No •
D.3.11.9	Recombinant medicinal product?	No •
D.3.11.10	Medicinal product containing genetically modified	No •

	organisms?	
D.3.11.10.1	Has the authorisation for contained use or release been granted?	No •
D.3.11.10.2	Is it pending?	No •
D.3.11.11	Herbal medicinal product?	No •
D.3.11.12	Homeopathic medicinal product?	No •
D.3.11.13	Another type of medicinal product?	No •
D.3.11.13.1	If 'another type of medicinal product' specify the type of medicinal product:	
D.3.12	Mode of action (<i>free text</i> ²⁰)	
D.3.13	Is it an IMP to be used in a first-in-human clinical trial?	No •
D.3.13.1	If 'Yes', are there risk factors identified, according to the guidance FIH? ²¹	

D.4	SOMATIC CELL THERAPY INVESTIGATIONAL MEDICINAL PRODUCT (NO GENETIC MODIFICATION)	
------------	---	--

D.4.1	Origin of cells	
D.4.1.1	Autologous	No •
D.4.1.2	Allogeneic	No •
D.4.1.3	Xenogeneic	No •
D.4.1.3.1	If 'Yes', specify the species of origin:	
D.4.2	Type of cells	
D.4.2.1	Stem cells	No •
D.4.2.2	Differentiated cells	No •
D.4.2.2.1	If 'Yes', specify the type (e.g. keratinocytes, fibroblasts, chondrocytes...):	
D.4.2.3	Others:	No •
D.4.2.3.1	If others, specify:	

D.5	GENE THERAPY INVESTIGATIONAL MEDICINAL PRODUCTS	
------------	--	--

D.5.1	Gene(s) of interest:	
D.5.2	In vivo gene therapy:	No •
D.5.3	Ex vivo gene therapy:	No •
D.5.4	Type of gene transfer product	
D.5.4.1	Nucleic acid (e.g. plasmid):	No •
	If 'Yes', specify if:	
D.5.4.1.1	Naked:	No •
D.5.4.1.2	Complexed	No •
D.5.4.2	Viral vector:	No •
D.5.4.2.1	If 'Yes', specify the type: adenovirus, retrovirus, AAV, ...:	
D.5.4.3	Others	No •
D.5.4.3.1	If others, specify:	
D.5.5	Genetically modified somatic cells:	No •
	If 'Yes', specify the origin of the cells:	
D.5.5.1	Autologous:	No •
D.5.5.2	Allogeneic:	No •
D.5.5.3	Xenogeneic:	No •
D.5.5.3.1	If 'Yes', specify the species of origin:	
D.5.5.4	Specify type of cells (hematopoietic stem cells...):	

D.6	TISSUE ENGINEERED PRODUCT	
------------	----------------------------------	--

The indication which determines that this is a Tissue Engineered Product as opposed to a Cell Therapy product is given in section E.1.1.

D.6.1	Origin of cells	
-------	-----------------	--

D.6.1.1	Autologous	No •
D.6.1.2	Allogeneic	No •
D.6.1.3	Xenogeneic	No •
D.6.1.3.1	If 'Yes', specify the species of origin:	
D.6.2	Type of cells	
D.6.2.1	Stem cells	No •
D.6.2.2	Differentiated cells	No •
D.6.2.2.1	If 'Yes', specify the type of cells(e.g. keratinocytes, fibroblasts, chondrocytes, ...):	
D.6.2.3	Others:	No •
D.6.2.3.1	If others, specify:	

D.7	PRODUCTS CONTAINING DEVICES (i.e. MEDICAL DEVICES, SCAFFOLDS ETC.)	
D.7.1	Give a brief description of the device:	
D.7.2	What is the name of the device?	
D.7.3	Is the device implantable?	No •
D.7.4	Does this product contain:	
D.7.4.1	A medical device?	No •
D.7.4.1.1	Does this medical device have a CE mark?	No •
D.7.4.1.1.1	The notified body is:	
D.7.4.2	Bio-materials?	No •
D.7.4.3	Scaffolds?	No •
D.7.4.4	Matrices?	No •
D.7.4.5	Other?	No •
D.7.4.5.1	If other, specify:	

D.1	IMP IDENTIFICATION	
Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial (assign numbers from 1-n):		
D.1.1	This refers to the IMP number:	PR3
D.1.2	IMP being tested	Yes •
D.1.3	IMP used as a comparator	No •

D.2	STATUS OF THE IMP	
D.2.1	Has the IMP to be used in the trial a marketing authorisation?	Yes •
If the IMP has a marketing authorisation in the Member State concerned by this application, but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2.		
D.2.1.1	If 'Yes', specify the product to be used in the clinical trial:	
D.2.1.1.1	Trade name	
D.2.1.1.1.1	EV Product Code (where applicable)	
D.2.1.1.2	Name of the Marketing Authorisation Holder:	
D.2.1.1.3	Marketing Authorisation number (if Marketing Authorisation granted by a Member State):	
D.2.1.1.4	Is the IMP modified in relation to its Marketing Authorisation?	No •
D.2.1.1.4.1	If 'Yes', please specify:	
D.2.1.2	The country that granted the Marketing Authorisation	Denmark
D.2.1.2.1	Is this the Member State concerned with this application?	Yes •

D.2.2	Situations where an IMP to be used in the CT has a Marketing Authorisation in the Member State concerned, but the protocol allows that any brand of the IMP with a Marketing Authorisation in that Member State be administered to the trial subjects and it is not possible to clearly identify
-------	--

	the IMP(s) in advance of the trial start	
D.2.2.1	In the protocol, is treatment defined only by active substance?	No •
D.2.2.1.1	If 'Yes', give active substance in D.3.8 or D.3.9	
D.2.2.2	In the protocol, do treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS?	No •
D.2.2.2.1	If 'Yes', give active substance in D.3.8 or D.3.9	
D.2.2.3	The products to be administered as IMPs are defined as belonging to an ATC group ⁹	Yes •
D.2.2.3.1	If 'Yes', give the ATC group of the applicable authorised codes in the ATC code field (level 3 or the level that can be defined) in D.3.3	
D.2.2.4	Other:	No •
D.2.2.4.1	If 'Yes', please specify:	

D.2.3	IMPD submitted:	
D.2.3.1	Full IMPD:	No •
D.2.3.2	Simplified IMPD:	No •
D.2.3.3	Summary of product characteristics (SmPC) only:	Yes •
D.2.4	Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community?	Yes •
D.2.4.1	If 'Yes' specify which Member States:	Denmark Finland
D.2.5	Has the IMP been designated in this indication as an orphan drug in the Community?	No •
D.2.5.1	If 'Yes', give the orphan drug designation number ¹⁰ :	

D.2.6	Has the IMP been the subject of scientific advice related to this clinical trial?	No •
D.2.6.1	If 'Yes' to D.2.6, please indicate source of advice and provide a copy in the CTA request:	
D.2.6.1.1	CHMP ¹¹ ?	No •
D.2.6.1.2	National Competent Authority?	No •

D.3	DESCRIPTION OF THE IMP	
D.3.1	Product name where applicable ¹² :	
D.3.2	Product code where applicable ¹³ :	
D.3.3	ATC codes, if officially registered ¹⁴ :	B05BB01
D.3.4	Pharmaceutical form (use standard terms):	Solution for infusion
D.3.4.1	Is this a specific paediatric formulation?	No •
D.3.5	Maximum duration of treatment of a subject according to the protocol:	
D.3.6	Dose allowed:	
D.3.6.1	For first trial only: Specify per day or total Specify total dose (number and unit): Route of administration (relevant to the first dose):	Total •
D.3.6.2	For all trials Specify per day or total Specify total dose (number and unit): Route of administration (relevant to the maximum dose):	Total • Intravenous use
D.3.7	Routes of administration (use standard terms):	Intravenous use

D.3.8	Name of each active substance (INN or proposed INN if available): Plasmalyte	
-------	--	--

D.3.9	Other available name for each active substance (provide all available):	
D.3.9.1	CAS ¹⁵ number	
D.3.9.2	Current sponsor code	
D.3.9.3	Other descriptive name	
	PLASMALYTE-A	
D.3.9.4	EV Substance code	SUB118335
D.3.9.5	Full Molecular formula	
D.3.9.6	Chemical/biological description of the Active Substance	
D.3.10	Strength (specify all strengths to be used):	
D.3.10.1	Concentration unit:	
D.3.10.2	Concentration type ("exact number", "range", "more than" or "up to"):	
D.3.10.3	Concentration (number).	

D.3.11	Type of IMP	
Does the IMP contain an active substance:		
D.3.11.1	Of chemical origin?	Yes ●
D.3.11.2	Of biological / biotechnological origin (other than Advanced Therapy IMP (ATIMP))?	No ●
Is this a:		
D.3.11.3	Advanced Therapy IMP (ATIMP)?	No ●
D.3.11.3.1	Somatic cell therapy medicinal product ¹⁶ ?	No ●
D.3.11.3.2	Gene therapy medicinal product ¹⁷ ?	No ●
D.3.11.3.3	Tissue Engineered Product ¹⁸ ?	No ●
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device ¹⁹)?	No ●
D.3.11.3.5	Has the Committee on Advanced Therapies issued a classification for this product?	No ●
D.3.11.3.5.1	If 'Yes' please provide that classification and its reference number:	
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy?	No ●
D.3.11.5	Radiopharmaceutical medicinal product?	No ●
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)?	No ●
D.3.11.7	Plasma derived medicinal product?	No ●
D.3.11.8	Extractive medicinal product?	No ●
D.3.11.9	Recombinant medicinal product?	No ●
D.3.11.10	Medicinal product containing genetically modified organisms?	No ●
D.3.11.10.1	Has the authorisation for contained use or release been granted?	No ●
D.3.11.10.2	Is it pending?	No ●
D.3.11.11	Herbal medicinal product?	No ●
D.3.11.12	Homeopathic medicinal product?	No ●
D.3.11.13	Another type of medicinal product?	No ●
D.3.11.13.1	If 'another type of medicinal product' specify the type of medicinal product:	
D.3.12	Mode of action (<i>free text</i> ²⁰)	
D.3.13	Is it an IMP to be used in a first-in-human clinical trial?	No ●
D.3.13.1	If 'Yes', are there risk factors identified, according to the guidance FIH? ²¹	

D.4	SOMATIC CELL THERAPY INVESTIGATIONAL MEDICINAL PRODUCT (NO GENETIC MODIFICATION)	
D.4.1	Origin of cells	
D.4.1.1	Autologous	No ●
D.4.1.2	Allogeneic	No ●

D.4.1.3	Xenogeneic	No •
D.4.1.3.1	If 'Yes', specify the species of origin:	
D.4.2	Type of cells	
D.4.2.1	Stem cells	No •
D.4.2.2	Differentiated cells	No •
D.4.2.2.1	If 'Yes', specify the type (e.g. keratinocytes, fibroblasts, chondrocytes...):	
D.4.2.3	Others:	No •
D.4.2.3.1	If others, specify:	

D.5 GENE THERAPY INVESTIGATIONAL MEDICINAL PRODUCTS		
D.5.1	Gene(s) of interest:	
D.5.2	In vivo gene therapy:	No •
D.5.3	Ex vivo gene therapy:	No •
D.5.4	Type of gene transfer product	
D.5.4.1	Nucleic acid (e.g. plasmid):	No •
	If 'Yes', specify if:	
D.5.4.1.1	Naked:	No •
D.5.4.1.2	Complexed	No •
D.5.4.2	Viral vector:	No •
D.5.4.2.1	If 'Yes', specify the type: adenovirus, retrovirus, AAV, ...:	
D.5.4.3	Others	No •
D.5.4.3.1	If others, specify:	
D.5.5	Genetically modified somatic cells:	No •
	If 'Yes', specify the origin of the cells:	
D.5.5.1	Autologous:	No •
D.5.5.2	Allogeneic:	No •
D.5.5.3	Xenogeneic:	No •
D.5.5.3.1	If 'Yes', specify the species of origin:	
D.5.5.4	Specify type of cells (hematopoietic stem cells...):	

D.6 TISSUE ENGINEERED PRODUCT		
The indication which determines that this is a Tissue Engineered Product as opposed to a Cell Therapy product is given in section E.1.1.		
D.6.1	Origin of cells	
D.6.1.1	Autologous	No •
D.6.1.2	Allogeneic	No •
D.6.1.3	Xenogeneic	No •
D.6.1.3.1	If 'Yes', specify the species of origin:	
D.6.2	Type of cells	
D.6.2.1	Stem cells	No •
D.6.2.2	Differentiated cells	No •
D.6.2.2.1	If 'Yes', specify the type of cells(e.g. keratinocytes, fibroblasts, chondrocytes, ...):	
D.6.2.3	Others:	No •
D.6.2.3.1	If others, specify:	

D.7 PRODUCTS CONTAINING DEVICES (i.e. MEDICAL DEVICES, SCAFFOLDS ETC.)	
D.7.1	Give a brief description of the device:
D.7.2	What is the name of the device?
D.7.3	Is the device implantable? No •
D.7.4	Does this product contain:
D.7.4.1	A medical device? No •
D.7.4.1.1	Does this medical device have a CE mark? No •
D.7.4.1.1.1	The notified body is:
D.7.4.2	Bio-materials? No •
D.7.4.3	Scaffolds? No •
D.7.4.4	Matrices? No •
D.7.4.5	Other? No •
D.7.4.5.1	If other, specify:

D.1 IMP IDENTIFICATION	
Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial (assign numbers from 1-n):	
D.1.1	This refers to the IMP number: PR4
D.1.2	IMP being tested Yes •
D.1.3	IMP used as a comparator No •

D.2 STATUS OF THE IMP	
D.2.1	Has the IMP to be used in the trial a marketing authorisation? Yes • If the IMP has a marketing authorisation in the Member State concerned by this application, but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2.
D.2.1.1	If 'Yes', specify the product to be used in the clinical trial:
D.2.1.1.1	Trade name
D.2.1.1.1.1	EV Product Code (where applicable)
D.2.1.1.2	Name of the Marketing Authorisation Holder:
D.2.1.1.3	Marketing Authorisation number (if Marketing Authorisation granted by a Member State):
D.2.1.1.4	Is the IMP modified in relation to its Marketing Authorisation? No •
D.2.1.1.4.1	If 'Yes', please specify:
D.2.1.2	The country that granted the Marketing Authorisation Denmark
D.2.1.2.1	Is this the Member State concerned with this application? Yes •

D.2.2	Situations where an IMP to be used in the CT has a Marketing Authorisation in the Member State concerned, but the protocol allows that any brand of the IMP with a Marketing Authorisation in that Member State be administered to the trial subjects and it is not possible to clearly identify the IMP(s) in advance of the trial start
D.2.2.1	In the protocol, is treatment defined only by active substance? No •
D.2.2.1.1	If 'Yes', give active substance in D.3.8 or D.3.9
D.2.2.2	In the protocol, do treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS? No •
D.2.2.2.1	If 'Yes', give active substance in D.3.8 or D.3.9
D.2.2.3	The products to be administered as IMPs are defined as belonging to an ATC group ⁹ Yes •
D.2.2.3.1	If 'Yes', give the ATC group of the applicable authorised codes in the ATC code field (level 3 or the level that can be defined) in D.3.3

D.2.2.4	Other:	No •
D.2.2.4.1	If 'Yes', please specify:	

D.2.3	IMPD submitted:	
D.2.3.1	Full IMPD:	No •
D.2.3.2	Simplified IMPD:	No •
D.2.3.3	Summary of product characteristics (SmPC) only:	Yes •
D.2.4	Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community?	Yes •
D.2.4.1	If 'Yes' specify which Member States:	Denmark Finland
D.2.5	Has the IMP been designated in this indication as an orphan drug in the Community?	No •
D.2.5.1	If 'Yes', give the orphan drug designation number ¹⁰ :	

D.2.6	Has the IMP been the subject of scientific advice related to this clinical trial?	No •
D.2.6.1	If 'Yes' to D.2.6, please indicate source of advice and provide a copy in the CTA request:	
D.2.6.1.1	CHMP ¹¹ ?	No •
D.2.6.1.2	National Competent Authority?	No •

D.3 DESCRIPTION OF THE IMP		
D.3.1	Product name where applicable ¹² :	
D.3.2	Product code where applicable ¹³ :	
D.3.3	ATC codes, if officially registered ¹⁴ :	B05BB01
D.3.4	Pharmaceutical form (use standard terms):	Solution for infusion
D.3.4.1	Is this a specific paediatric formulation?	No •
D.3.5	Maximum duration of treatment of a subject according to the protocol:	
D.3.6	Dose allowed:	
D.3.6.1	For first trial only: Specify per day or total	Total •
	Specify total dose (number and unit): Route of administration (relevant to the first dose):	
D.3.6.2	For all trials Specify per day or total	Total •
	Specify total dose (number and unit): Route of administration (relevant to the maximum dose):	Intravenous use
D.3.7	Routes of administration (use standard terms):	Intravenous use

D.3.8	Name of each active substance (INN or proposed INN if available):	
	Ringers Lactate	
D.3.9	Other available name for each active substance (provide all available):	
D.3.9.1	CAS ¹⁵ number	8026-79-7
D.3.9.2	Current sponsor code	
D.3.9.3	Other descriptive name	
	RINGER'S LACTATE SOLUTION	
D.3.9.4	EV Substance code	SUB33298
D.3.9.5	Full Molecular formula	
D.3.9.6	Chemical/biological description of the Active Substance	
D.3.10	Strength (specify all strengths to be used):	
D.3.10.1	Concentration unit:	
D.3.10.2	Concentration type ("exact number", "range", "more than" or "up to"):	

D.3.10.3 Concentration (number).

D.3.11	Type of IMP	
Does the IMP contain an active substance:		
D.3.11.1	Of chemical origin?	Yes ●
D.3.11.2	Of biological / biotechnological origin (other than Advanced Therapy IMP (ATIMP)?	No ●
Is this a:		
D.3.11.3	Advanced Therapy IMP (ATIMP)?	No ●
D.3.11.3.1	Somatic cell therapy medicinal product ¹⁶ ?	No ●
D.3.11.3.2	Gene therapy medicinal product ¹⁷ ?	No ●
D.3.11.3.3	Tissue Engineered Product ¹⁸ ?	No ●
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device ¹⁹)?	No ●
D.3.11.3.5	Has the Committee on Advanced Therapies issued a classification for this product?	No ●
D.3.11.3.5.1	If 'Yes' please provide that classification and its reference number:	
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy?	No ●
D.3.11.5	Radiopharmaceutical medicinal product?	No ●
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)?	No ●
D.3.11.7	Plasma derived medicinal product?	No ●
D.3.11.8	Extractive medicinal product?	No ●
D.3.11.9	Recombinant medicinal product?	No ●
D.3.11.10	Medicinal product containing genetically modified organisms?	No ●
D.3.11.10.1	Has the authorisation for contained use or release been granted?	No ●
D.3.11.10.2	Is it pending?	No ●
D.3.11.11	Herbal medicinal product?	No ●
D.3.11.12	Homeopathic medicinal product?	No ●
D.3.11.13	Another type of medicinal product?	No ●
D.3.11.13.1	If 'another type of medicinal product' specify the type of medicinal product:	
D.3.12	Mode of action (<i>free text</i> ²⁰)	
D.3.13	Is it an IMP to be used in a first-in-human clinical trial?	No ●
D.3.13.1	If 'Yes', are there risk factors identified, according to the guidance FIH? ²¹	

D.4	SOMATIC CELL THERAPY INVESTIGATIONAL MEDICINAL PRODUCT (NO GENETIC MODIFICATION)	
D.4.1	Origin of cells	
D.4.1.1	Autologous	No ●
D.4.1.2	Allogeneic	No ●
D.4.1.3	Xenogeneic	No ●
D.4.1.3.1	If 'Yes', specify the species of origin:	
D.4.2	Type of cells	
D.4.2.1	Stem cells	No ●
D.4.2.2	Differentiated cells	No ●
D.4.2.2.1	If 'Yes', specify the type (e.g. keratinocytes, fibroblasts, chondrocytes...):	
D.4.2.3	Others:	No ●
D.4.2.3.1	If others, specify:	

D.5 GENE THERAPY INVESTIGATIONAL MEDICINAL PRODUCTS

D.5.1	Gene(s) of interest:	
D.5.2	In vivo gene therapy:	No ●
D.5.3	Ex vivo gene therapy:	No ●
D.5.4	Type of gene transfer product	
D.5.4.1	Nucleic acid (e.g. plasmid):	No ●
	If 'Yes', specify if:	
D.5.4.1.1	Naked:	No ●
D.5.4.1.2	Complexed	No ●
D.5.4.2	Viral vector:	No ●
D.5.4.2.1	If 'Yes', specify the type: adenovirus, retrovirus, AAV, ...:	
D.5.4.3	Others	No ●
D.5.4.3.1	If others, specify:	
D.5.5	Genetically modified somatic cells:	No ●
	If 'Yes', specify the origin of the cells:	
D.5.5.1	Autologous:	No ●
D.5.5.2	Allogeneic:	No ●
D.5.5.3	Xenogeneic:	No ●
D.5.5.3.1	If 'Yes', specify the species of origin:	
D.5.5.4	Specify type of cells (hematopoietic stem cells...):	

D.6 TISSUE ENGINEERED PRODUCT		
The indication which determines that this is a Tissue Engineered Product as opposed to a Cell Therapy product is given in section E.1.1.		
D.6.1	Origin of cells	
D.6.1.1	Autologous	No ●
D.6.1.2	Allogeneic	No ●
D.6.1.3	Xenogeneic	No ●
D.6.1.3.1	If 'Yes', specify the species of origin:	
D.6.2	Type of cells	
D.6.2.1	Stem cells	No ●
D.6.2.2	Differentiated cells	No ●
D.6.2.2.1	If 'Yes', specify the type of cells(e.g. keratinocytes, fibroblasts, chondrocytes, ...):	
D.6.2.3	Others:	No ●
D.6.2.3.1	If others, specify:	

D.7 PRODUCTS CONTAINING DEVICES (i.e. MEDICAL DEVICES, SCAFFOLDS ETC.)		
D.7.1	Give a brief description of the device:	
D.7.2	What is the name of the device?	
D.7.3	Is the device implantable?	No ●
D.7.4	Does this product contain:	
D.7.4.1	A medical device?	No ●
D.7.4.1.1	Does this medical device have a CE mark?	No ●
D.7.4.1.1.1	The notified body is:	
D.7.4.2	Bio-materials?	No ●
D.7.4.3	Scaffolds?	No ●
D.7.4.4	Matrices?	No ●
D.7.4.5	Other?	No ●
D.7.4.5.1	If other, specify:	

D.8 INFORMATION ON PLACEBO (if relevant; repeat as necessary)

D.8.1	Is there a placebo:	No •
D.8.2	This refers to placebo number:	
D.8.3	Pharmaceutical form:	
D.8.4	Route of administration:	
D.8.5	Which IMP is it a placebo for? Specify IMP Number(s) from D.1.1	
D.8.5.1	Composition, apart from the active substance(s):	
D.8.5.2	Is it otherwise identical to the IMP?	Yes ? No ? Not Answered ?
D.8.5.2.1	If not, specify major ingredients:	

D.9 SITE(S) WHERE THE QUALIFIED PERSON CERTIFIES BATCH RELEASE²²

This section is dedicated to **finished** IMPs, i.e. medicinal products randomised, packaged, labelled and certified for use in the clinical trial. If there is more than one site or more than one IMP is certified, use extra pages and give each IMP its number from section D.1.1 or D.8.2 In the case of multiple sites indicate the product certified by each site

D.9.1	Do not fill in section D.9.2 for an IMP that: <i>Has a MA in the EU and</i> <i>Is sourced from the EU market and</i> <i>Is used in the trial without modification(e.g. not overencapsulated) and</i> <i>The packaging and labelling is carried out for local use only as per article 9.2. of the Directive 2005/28/EC (GCP Directive)</i> If all these conditions are met tick ?and list the number(s) of each IMP including placebo from sections D.1.1 and D.8.2 to which this applies PR1
-------	---

D.9.2	Who is responsible in the Community for the certification of the finished IMPs?
	This site is responsible for certification of (list the number(s) of each IMP including placebo from sections D.1.1 and D.8.2): please tick the appropriate box:
D.9.2.1	Manufacturer ?
D.9.2.2	Importer ?
D.9.2.3	Name of the organisation:
D.9.2.4	Address:
D.9.2.4.1	Street Address
D.9.2.4.2	Town/City
D.9.2.4.3	Post Code
D.9.2.4.4	Country
D.9.2.5	Give the manufacturing authorisation number:
D.9.2.5.1	If No authorisation, give the reasons:
<i>Where the product does not have a MA in the EU, but is supplied in bulk and final packaging and labelling for local use is carried out in accordance with article 9.2 of Directive 2005/28/EC (GCP Directive) then enter the site where the product was finally certified for release by the Qualified Person for use in the clinical trial at D.9.2 above.</i>	

E. GENERAL INFORMATION ON THE TRIAL

This section should be used to provide information about the aims, scope and design of the trial. When the protocol includes a sub-study in the MS concerned section E.2.3 should be completed providing information about the sub-study. To identify it check the sub-study box in the 'Objective of the trial' question below.

E.1 MEDICAL CONDITION OR DISEASE UNDER INVESTIGATION					
E.1.1	Specify the medical condition(s) to be investigated ²³ (free text): English Septic shock				
E.1.1.1	Medical condition in easily understood language English Sepsis with severe circulatory impairment				
E.1.1.2	Therapeutic area Diseases [C] - Bacterial Infections and Mycoses [C01]				
E.1.2	MedDRA version, system organ class, level, term and classification code ²⁴ :				
	Version	System Organ Class	Classification Code	Term	Level
	20.0	100000004862	10040050	Sepsis NOS	LLT
E.1.3	Is any of the conditions being studied a rare disease ²⁵ ?				No •
E.2 OBJECTIVE OF THE TRIAL					
E.2.1	Main objective: English The objective of the CLASSIC trial is to assess benefits and harms of IV fluid restriction vs. standard of care on patient-important outcome measures in adult ICU patients with septic shock.				
E.2.2	Secondary objectives: English Not applicable				
E.2.3	Is there a sub-study? No •				
E.2.3.1	If 'Yes', give the full title, date and version of each sub-study and their related objectives:				
E.3 PRINCIPAL INCLUSION CRITERIA (list the most important)					
	English	All the following criteria must be fulfilled: <input type="checkbox"/> Aged 18 years or above <input type="checkbox"/> Admitted to the ICU or plan to be admitted to the ICU regardless of trial participation <input type="checkbox"/> Septic shock defined according to the Sepsis-3 criteria: <input type="checkbox"/> Suspected or confirmed site of infection or positive blood culture AND <input type="checkbox"/> Ongoing infusion of vasopressor/inotrope agent to maintain a mean arterial blood pressure of 65 mmHg or above AND <input type="checkbox"/> Lactate of 2 mmol/L or above in any plasma sample performed within the last 3-hours <input type="checkbox"/> Have received at least 1 L of IV fluid (crystalloids, colloids or blood products) in the last 24-hours prior to screening.			
E.4 PRINCIPAL EXCLUSION CRITERIA (list the most important)					
	English	We will exclude patients who fulfil any of the following criteria: <input type="checkbox"/> Septic shock for more than 12 hours at the time of screening because we want to include patients early in their course <input type="checkbox"/> Life-threatening bleeding as these patients need specific fluid/blood product strategies <input type="checkbox"/> Acute burn injury of more than 10% of the body surface area as these patients need a specific fluid strategy			

- **Known pregnancy.**
- **Consent not obtainable as per the model approved for the specific site.**

E.5 END POINT(S):	
E.5.1	Primary End Point (repeat as necessary) ²⁶ English All-cause mortality at day 90 after randomisation
E.5.1.1	Timepoint(s) of evaluation of this end point English day 90 after randomisation
E.5.2	Secondary End Point (repeat as necessary) English <ul style="list-style-type: none"> - <input type="checkbox"/> Number of participants with one or more serious adverse events (SAEs) in the ICU defined as ischaemic events (cerebral, cardiac, intestinal or limb ischaemia) or as a new episode of severe acute kidney injury (modified KDIGO3) - <input type="checkbox"/> Number of participants with one or more serious adverse reactions (SARs) to IV crystalloids in the ICU. - <input type="checkbox"/> Days alive at day 90 without life support (vasopressor / inotropic support, invasive mechanical ventilation or renal replacement therapy) - <input type="checkbox"/> Days alive and out of hospital at day 90 - <input type="checkbox"/> All-cause mortality at 1-year after randomisation - <input type="checkbox"/> HRQoL 1-year after randomisation measured using the EuroQoL (EQ)-5D-5L and EQ-VAS scores. Participants who have died will be assigned the lowest possible scores - <input type="checkbox"/> Cognitive function 1-year after randomisation as assessed by the Montreal Cognitive Assessment (MoCa) score
E.5.2.1	Timepoint(s) of evaluation of this end point English during ICU admission, day 90 after randomisation or 1 year after randomisation

E.6 SCOPE OF THE TRIAL – Tick all boxes where applicable	
E.6.1	Diagnosis No •
E.6.2	Prophylaxis No •
E.6.3	Therapy Yes •
E.6.4	Safety Yes •
E.6.5	Efficacy Yes •
E.6.6	Pharmacokinetic No •
E.6.7	Pharmacodynamic No •
E.6.8	Bioequivalence No •
E.6.9	Dose Response No •
E.6.10	Pharmacogenetic No •
E.6.11	Pharmacogenomic No •
E.6.12	Pharmacoeconomic No •
E.6.13	Others No •
E.6.13.1	If others, specify:

E.7 TRIAL TYPE AND PHASE²⁷	
E.7.1	Human pharmacology (Phase I) No •
Is it:	
E.7.1.1	First administration to humans No •
E.7.1.2	Bioequivalence study No •

E.7.1.3	Other:	No •
E.7.1.3.1	If other, please specify:	
E.7.2	Therapeutic exploratory (Phase II)	No •
E.7.3	Therapeutic confirmatory (Phase III)	No •
E.7.4	Therapeutic use(Phase IV)	Yes •

E.8 DESIGN OF THE TRIAL		
E.8.1	Controlled	Yes •
	If 'Yes', specify:	
E.8.1.1	Randomised:	Yes •
E.8.1.2	Open:	Yes •
E.8.1.3	Single blind:	No •
E.8.1.4	Double blind:	No •
E.8.1.5	Parallel group:	Yes •
E.8.1.6	Cross over:	No •
E.8.1.7	Other:	No •
E.8.1.7.1	If other specify:	
E.8.2	If controlled, specify the comparator:	
E.8.2.1	Other medicinal product(s)	No •
E.8.2.2	Placebo	No •
E.8.2.3	Other	Yes •
E.8.2.3.1	If 'Yes' to other, specify :	
	English fluid resuscitation reflecting standard care	
E.8.2.4	Number of treatment arms in the trial	2
E.8.3	Single site in the Member State concerned (see also section G):	No •
E.8.4	Multiple sites in the Member State concerned(see also section G):	Yes •
E.8.4.1	Number of sites anticipated in Member State concerned	12
E.8.5	Multiple Member States:	Yes •
E.8.5.1	Number of sites anticipated in the EEA:	35
E.8.6	Trial involving sites outside the EEA:	
E.8.6.1	Trial being conducted both within and outside the EEA:	Yes •
E.8.6.2	Trial being conducted completely outside of the EEA:	No •
E.8.6.3	If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:	
	Canada	
E.8.6.4	If E.8.6.1 or E.8.6.2 are Yes, specify the number of sites anticipated outside of the EEA:	1
E.8.7	Trial having an independent data monitoring committee:	Yes •
E.8.8	Definition of the end of trial: If it is the last visit of the last subject, please enter "LVLS". If it is not LVLS provide the definition:	
	English The trial will end when number of randomised patients reach 1554	
E.8.9	Initial estimate of the duration of the trial ²⁸ (years, months and days)	
E.8.9.1	In the Member State concerned	2 years months days
E.8.9.2	In all countries concerned by the trial	2 years months days
E.8.10	Proposed date of start of recruitment	
E.8.10.1	In the Member State concerned	2018-09-01
E.8.10.2	In any country	

F. POPULATION OF TRIAL SUBJECTS

F.1 AGE RANGE		
F.1.1	Are the trial subjects under 18? If 'Yes', specify the estimated number of subjects planned in each age range for the whole trial:	No •
	Approx. No. of patients ²⁹	
F.1.1.1	In utero	() No •
F.1.1.2	Preterm newborn infants (up to gestational age < 37 weeks)	() No •
F.1.1.3	Newborns (0-27 days)	() No •
F.1.1.4	Infants and toddlers (28 days - 23 months)	() No •
F.1.1.5	Children (2-11 years)	() No •
F.1.1.6	Adolescents (12-17 years)	() No •
F.1.2	Adults (18-64 years)	(754) Yes •
F.1.3	Elderly (>= 65 years)	(800) Yes •

F.2 GENDER		
F.2.1	Female	Yes •
F.2.2	Male	Yes •

F.3 GROUP OF TRIAL SUBJECTS		
F.3.1	Healthy volunteers	No •
F.3.2	Patients	Yes •
F.3.3	Specific vulnerable populations	Yes •
F.3.3.1	Women of child bearing potential not using contraception	Yes •
F.3.3.2	Women of child bearing potential using contraception	Yes •
F.3.3.3	Pregnant women	No •
F.3.3.4	Nursing women	Yes •
F.3.3.5	Emergency situation	Yes •
F.3.3.6	Subjects incapable of giving consent personally	Yes •
F.3.3.6.1	If 'Yes', specify: English The trial cannot be performed in conscious persons, as no clinically relevant model of septic shock exists and no conscious patients have the combination of severe infection and shock as septic patients have.	
F.3.3.7	Others:	No •
F.3.3.7.1	If 'Yes', specify:	

F.4 PLANNED NUMBER OF SUBJECTS TO BE INCLUDED:		
F.4.1	In the member state	800
F.4.2	For a multinational trial:	
F.4.2.1	In the EEA	754
F.4.2.2	In the whole clinical trial	1554

F.5 PLANS FOR TREATMENT OR CARE AFTER THE SUBJECT HAS ENDED HIS/HER PARTICIPATION IN THE TRIAL. please specify (free text):		
English	None	

G. CLINICAL TRIAL SITES/INVESTIGATORS IN THE MEMBER STATE CONCERNED BY THIS REQUEST

G.1	CO-ORDINATING INVESTIGATOR (for multicentre trial) and principal investigator (for single centre trial)	
G.1.1	Given name:	Mette
G.1.2	Middle name, if applicable:	
G.1.3	Family name:	Krag Vogelius
G.1.4	Qualification (MD.....)	MD
G.1.5	Professional address:	
G.1.5	Institution name	Holbæk Hospital
G.1.5	Institution department	Dept. of Intensive Care
G.1.5.1	Street address	Smedelundsgade 60
G.1.5.2	Town/city	Holbæk
G.1.5.3	Post code	4300
G.1.5.4	Country	Denmark
G.1.6	Telephone number:	
G.1.7	Fax number:	
G.1.8	E-mail:	mevo@regionsjaelland.dk

G.1	CO-ORDINATING INVESTIGATOR (for multicentre trial) and principal investigator (for single centre trial)	
G.1.1	Given name:	Tine
G.1.2	Middle name, if applicable:	Sylvest
G.1.3	Family name:	Meyhoff
G.1.4	Qualification (MD.....)	MD
G.1.5	Professional address:	
G.1.5	Institution name	Copenhagen University Hospital, Rigshospitalet
G.1.5	Institution department	Dept. of Intensive Care
G.1.5.1	Street address	Blegdamsvej 9
G.1.5.2	Town/city	Copenhagen
G.1.5.3	Post code	2100
G.1.5.4	Country	Denmark
G.1.6	Telephone number:	
G.1.7	Fax number:	
G.1.8	E-mail:	tine.sylvest.meyhoff@regionh.dk

G.2	PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)	
G.2.1	Given name:	Morten
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	Bestle
G.2.4	Qualification (MD.....)	senior staff specialist and associate professor
G.2.5	Professional address:	
G.2.5	Institution name	Copenhagen University Hospital, North Zealand Hospital
G.2.5	Institution department	Dept. of Anaesthesia and Intensive Care
G.2.5.1	Street address	Dyrehavevej 29
G.2.5.2	Town/city	Hillerød
G.2.5.3	Post code	3400
G.2.5.4	Country	Denmark
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	morten.bestle@regionh.dk

G.2	PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)	
------------	--	--

G.2.1	Given name:	Lars
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	Nebrich
G.2.4	Qualification (MD.....)	senior staff specialist
G.2.5	Professional address:	
G.2.5	Institution name	Zealand University Hospital, Køge
G.2.5	Institution department	Dept. of Anaesthesia and Intensive Care
G.2.5.1	Street address	
G.2.5.2	Town/city	Køge
G.2.5.3	Post code	4600
G.2.5.4	Country	Denmark
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	Inec@regionsjaelland.dk

G.2	PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)	
G.2.1	Given name:	Thomas
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	Hildebrandt
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	Zealand University Hospital, Roskilde
G.2.5	Institution department	Dept. of Intensive Care
G.2.5.1	Street address	
G.2.5.2	Town/city	Roskilde
G.2.5.3	Post code	4000
G.2.5.4	Country	Denmark
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	thi@regionsjaelland.dk

G.2	PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)	
G.2.1	Given name:	Michael
G.2.2	Middle name, if applicable:	Lindhardt
G.2.3	Family name:	Rasmussen
G.2.4	Qualification (MD.....)	MD
G.2.5	Professional address:	
G.2.5	Institution name	Herning Hospital
G.2.5	Institution department	Dept. of Intensive Care
G.2.5.1	Street address	
G.2.5.2	Town/city	
G.2.5.3	Post code	
G.2.5.4	Country	Denmark
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	Michael.Lindhardt.Rasmussen@vest.rm.dk

G.2	PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)	
G.2.1	Given name:	Louise
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	Bendix Kiel
G.2.4	Qualification (MD.....)	MD
G.2.5	Professional address:	

G.2.5	Institution name	Copenhagen University Hospital, Bispebjerg
G.2.5	Institution department	Dept. of Intensive Care
G.2.5.1	Street address	Bispebjerg Bakke 23
G.2.5.2	Town/city	Copenhagen
G.2.5.3	Post code	2400
G.2.5.4	Country	Denmark
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	louise.bendix.kiel.01@regionh.dk

G.2	PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)	
G.2.1	Given name:	Henrik
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	Christensen
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	Copenhagen University Hospital, Herlev
G.2.5	Institution department	Dept. of Intensive Care
G.2.5.1	Street address	
G.2.5.2	Town/city	
G.2.5.3	Post code	
G.2.5.4	Country	Denmark
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	henrik.christensen@regionh.dk

G.2	PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)	
G.2.1	Given name:	Marianne
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	Vang
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	Randers Hospital
G.2.5	Institution department	Dept. of Intensive Care
G.2.5.1	Street address	
G.2.5.2	Town/city	
G.2.5.3	Post code	
G.2.5.4	Country	Denmark
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	marivang@rm.dk

G.2	PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)	
G.2.1	Given name:	Christoffer
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	Sølling
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	Viborg Hospital
G.2.5	Institution department	Dept. of Intensive Care
G.2.5.1	Street address	
G.2.5.2	Town/city	
G.2.5.3	Post code	
G.2.5.4	Country	Denmark

G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	chrsoell@rm.dk

G.2	PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)	
G.2.1	Given name:	Bodil
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	Rasmussen
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	Aalborg University Hospital
G.2.5	Institution department	Dept. of Intensive Care
G.2.5.1	Street address	
G.2.5.2	Town/city	
G.2.5.3	Post code	
G.2.5.4	Country	Denmark
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	bodil.steen.rasmussen@rn.dk

G.2	PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)	
G.2.1	Given name:	Louise
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	Gyldensted
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	Copenhagen University Hospital, Gentofte
G.2.5	Institution department	Dept. of Intensive Care
G.2.5.1	Street address	
G.2.5.2	Town/city	
G.2.5.3	Post code	
G.2.5.4	Country	Denmark
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	louise.gyldensted.01@regionh.dk

G.2	PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)	
G.2.1	Given name:	Klaus
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	Marcussen
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	Slagelse Hospital
G.2.5	Institution department	Dept. of Intensive Care
G.2.5.1	Street address	
G.2.5.2	Town/city	
G.2.5.3	Post code	
G.2.5.4	Country	Denmark
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	klvm@regionsjaelland.dk

G.2 PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)		
G.2.1	Given name:	Anne
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	Craveiro Brøchner
G.2.4	Qualification (MD.....)	MD, PhD, Senior staff specialist
G.2.5	Professional address:	
G.2.5	Institution name	Kolding Hospital
G.2.5	Institution department	Dept. of Intensive Care
G.2.5.1	Street address	Sygehusvej 24
G.2.5.2	Town/city	Kolding
G.2.5.3	Post code	6000
G.2.5.4	Country	Denmark
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	Anne.Craveiro.Broechner@rsyd.dk

G.3 CENTRAL TECHNICAL FACILITIES TO BE USED IN THE CONDUCT OF THE TRIAL		
Laboratory or other technical facility, in which the measurement or assessment of the main evaluation criteria are centralised (repeat as needed for multiple organisations).		
G.3.1	Name of organisation:	
G.3.2	Department	
G.3.3	Name of contact person:	
G.3.3.1	Given name	
G.3.3.2	Middle name	
G.3.3.3	Family name	
G.3.4	Address:	
G.3.4.1	Street address	
G.3.4.2	Town/city	
G.3.4.3	Post code	
G.3.4.4	Country	
G.3.5	Telephone number:	
G.3.6	Fax number:	
G.3.7	E-mail:	
G.3.8	Enter the details of any duties subcontracted to this central technical facility in this trial	
G.3.8.1	Routine clinical pathology testing	Yes ? No ? Not Answered ?
G.3.8.2	Clinical chemistry	Yes ? No ? Not Answered ?
G.3.8.3	Clinical haematology	Yes ? No ? Not Answered ?
G.3.8.4	Clinical microbiology	Yes ? No ? Not Answered ?
G.3.8.5	Histopathology	Yes ? No ? Not Answered ?
G.3.8.6	Serology/ endocrinology	Yes ? No ? Not Answered ?
G.3.8.7	Analytical chemistry	Yes ? No ? Not Answered ?
G.3.8.8	ECG analysis/ review	Yes ? No ? Not Answered ?
G.3.8.9	Medical image analysis/ review - X-ray, MRI, ultrasound, etc.	Yes ? No ? Not Answered ?
G.3.8.10	Primary/ surrogate endpoint test	Yes ? No ? Not Answered ?
G.3.8.11	Other Duties subcontracted?	Yes ? No ? Not Answered ?
G.3.8.11.1	If 'Yes', specify the other duties	

G.4 NETWORKS TO BE INVOLVED IN THE TRIAL (e.g. Paediatric Networks involved in the trial)		
G.4.1	Name of organisation:	Centre of Research in Intensive Care – CRIC
G.4.2	Name of contact person:	
G.4.2.1	Given name	
G.4.2.2	Middle name	
G.4.2.3	Family name	

G.4.3	Address:	
G.4.3.1	Street address	Tagensvej 22
G.4.3.2	Town/city	Copenhagen
G.4.3.3	Post code	2200
G.4.3.4	Country	Denmark
G.4.4	Telephone number:	0045 3545 7167
G.4.5	Fax number:	
G.4.6	E-mail:	contact@cric.nu
G.4.7	Activities carried out by the network:	Coordinating centre

G.4	NETWORKS TO BE INVOLVED IN THE TRIAL (e.g. Paediatric Networks involved in the trial)	
G.4.1	Name of organisation:	Copenhagen Trial Unit, Centre for Interventional Research
G.4.2	Name of contact person:	
G.4.2.1	Given name	
G.4.2.2	Middle name	
G.4.2.3	Family name	
G.4.3	Address:	
G.4.3.1	Street address	Tagensvej 22
G.4.3.2	Town/city	Copenhagen
G.4.3.3	Post code	2200
G.4.3.4	Country	Denmark
G.4.4	Telephone number:	0045 3545 7171
G.4.5	Fax number:	
G.4.6	E-mail:	
G.4.7	Activities carried out by the network:	Methods centre

G.5	ORGANISATIONS TO WHOM THE SPONSOR HAS TRANSFERRED TRIAL RELATED DUTIES AND FUNCTIONS	
G.5.1	Has the sponsor transferred any major or all the sponsor's trial related duties and functions to another organisation or third party?	Yes •
Repeat as necessary for multiple organisations:		
G.5.1.1	Organisation name:	Copenhagen University Hospital GCP Unit
G.5.1.2	Organisation department	
G.5.1.3	Name of contact person :	
G.5.1.3.1	Given name	
G.5.1.3.2	Middle name	
G.5.1.3.3	Family name	
G.5.1.4	Address:	
G.5.1.4.1	Street address	Bispebjerg Hospital, building 51, 3rd floor, Bispebjerg Bakke 23
G.5.1.4.2	Town/city	Copenhagen NV
G.5.1.4.3	Post code	2400
G.5.1.4.4	Country	Denmark
G.5.1.5	Telephone number:	0045 38635620
G.5.1.6	Fax number:	
G.5.1.7	E-mail:	
G.5.1.8	All tasks of the sponsor	No •
G.5.1.9	Monitoring	Yes •
G.5.1.10	Regulatory (e.g. preparation of applications to CA and ethics committee)	No •
G.5.1.11	Investigator recruitment	No •
G.5.1.12	IVRS ³⁰ – treatment randomisation	No •
G.5.1.13	Data management	No •
G.5.1.14	E-data capture	No •

G.5.1.15	SUSAR reporting	No •
G.5.1.16	Quality assurance auditing	No •
G.5.1.17	Statistical analysis	No •
G.5.1.18	Medical writing	No •
G.5.1.19	Other duties subcontracted?	No •
G.5.1.19.1	If 'Yes' to other, please specify:	

H. COMPETENT AUTHORITY / ETHICS COMMITTEE IN THE MEMBER STATE CONCERNED BY THIS REQUEST

H.1 TYPE OF APPLICATION		
If this application is addressed to the Competent Authority, please tick the Ethics Committee box and give information on the Ethics committee concerned. If this application is addressed to the Ethics Committee, please tick the Competent Authority box and give the information on the Competent Authority concerned.		
H.1.1	Competent Authority	No •
H.1.2	Ethics Committee	Yes •
H.2 INFORMATION ON ETHICS COMMITTEE		
H.2.1	Name:	The Committees for Health Research Ethics for the Capital Region of Denmark
H.2.2	Address	
H.2.2.1	Street address	Finsensvej 15
H.2.2.2	Town/city	Frederiksberg
H.2.2.3	Post code	2000
H.2.2.4	Country	Denmark
H.2.3	Date of submission:	
H.3 OPINION		
H.3.1	To be requested	Yes •
H.3.2	Pending	No •
H.3.3	Given	No •
	If 'Given', specify:	
H.3.3.1	Date of opinion:	
H.3.3.2	Opinion favourable	No •
H.3.3.3	Opinion not favourable	No •
	If not favourable, give:	
H.3.3.3.1	The reasons	
H.3.3.3.2	The eventual anticipated date of resubmission:	

I. SIGNATURE OF THE APPLICANT IN THE MEMBER STATE

I.1	I hereby confirm that /confirm on behalf of the sponsor (delete which is not applicable) that: <ul style="list-style-type: none">• the information provided is complete;• the attached documents contain an accurate account of the information available;• the clinical trial will be conducted in accordance with the protocol; and• the clinical trial will be conducted, and SUSARs and result-related information will be reported, in accordance with the applicable legislation.
------------	--

I.2	APPLICANT OF THE REQUEST FOR THE COMPETENT AUTHORITY (as stated in section C.1):
I.2.1	Date:
I.2.2	Signature ³¹ :
I.2.3	Print name:

I.3	APPLICANT OF THE REQUEST FOR THE ETHICS COMMITTEE (as stated in section C.2):
I.3.1	Date:
I.3.2	Signature ³² :
I.3.3	Print name:

ENDNOTES

- ¹ Any translation of the protocol should be assigned the same date and version as those in the original document.
- ² International Standard Randomised Controlled Trial Number. Sponsors may wish to use an International Standardised Random Controlled Trial Number (ISRCTN) to identify their trial in addition to the EudraCT number; for instance if their trial is part of a multinational trial with sites outside the Community. They can obtain the number and guidance from the Current Controlled Trials website <http://www.controlled-trials.com/isrctn> to which there is a link from the EudraCT database website <http://eudract.ema.europa.eu>. When available they should provide it in Section A.6 of the application form.
- ³ US National Clinical Trial (NCT) Numbers required on the FDA clinical trial application form.
- ⁴ For a resubmission following previous withdrawal of an application or unfavourable opinion of an ethics committee, or previous withdrawal of an application or refusal of a request by the competent authority, enter a letter in the sequence, A for first resubmission, B for second, C for third et seq.
- ⁵ In accordance with Article 19 of Directive 2001/20/EC.
- ⁶ The contact point should give functional information rather than details of one "person", in order to avoid the need for update and maintenance of these contact details.
- ⁷ This requires a EudraLink account. (See <https://eudract.ema.europa.eu/document.html> for details)
- ⁸ According to national legislation.
- ⁹ Available from the Summary of Product Characteristics (SmPC)
- ¹⁰ According to the Community register on orphan medicinal products (Regulation (EC) n° 141/2000): <http://ec.europa.eu/enterprise/pharmaceuticals/register/index.htm>
- ¹¹ Committee for Medicinal Products for Human Use of the European Medicines Agency
- ¹² To be provided only when there is No trade name. This is the name routinely used by a sponsor to identify the IMP in the CT documentation (protocol, IB...).
- ¹³ To be provided only when there is No trade name. This is a code designated by the sponsor which represents the name routinely used by the sponsor to identify the product in the CT documentation. For example, a code may be used for combinations of drugs or drugs and devices.
- ¹⁴ Available from the Summary of Product Characteristics (SmPC).
- ¹⁵ Chemical Abstracts Service.
- ¹⁶ Complete also section D.4 Cell therapy as defined in Annex 1 part IV of Directive 2001/83/EC as amended.
- ¹⁷ Complete also section D.5 Gene Therapy as defined in Annex 1 part IV of Directive 2001/83/EC as amended.
- ¹⁸ Complete also section D.6 - Tissue Engineered Product as defined in Article 2(1)(b) of Regulation 1394/2007/EC.
- ¹⁹ Complete also section D.7
- ²⁰ The mode of action should briefly describe the chemical, biochemical, immunological or biological means the IMP uses to effect its pharmaceutical action.
- ²¹ Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. EMEA/CHMP/SWP/28367/2007 19 July 2007
- ²² In accordance with paragraph 38 of Annex 13 of Volume 4 of the Rules Governing Medical Products in the European Union.
- ²³ In the case of healthy volunteer trials, the intended indication for the product under development should be provided.
- ²⁴ Applicants are encouraged to provide the MedDRA lower level term if applicable and classification code. These can be accessed from the EMEA EudraCT website (<http://eudract.ema.europa.eu/>).
- ²⁵ Points to consider on the calculation and reporting of the prevalence of a condition for Orphan drug designation: COM/436/01 (<http://www.ema.europa.eu/htms/human/orphans/intro.htm>).
- ²⁶ The protocol will usually identify a single primary end point but there may be a co-primary end point in some cases and/or a number of secondary end points.
- ²⁷ The descriptions of the trial types provided are those recommended in preference to Phases. See page 5 of Community guideline CPMP/ICH/291/95. The development of a new indication after initial approval of a medicine should be considered as a new development plan.
- ²⁸ From the first inclusion until the last visit of the last subject.
- ²⁹ These numbers will be initial estimates. Applicants will not be required to update this information nor do they constitute an authorisation or restriction on the inclusion of these numbers of patients in the trial. The numbers of subjects whose inclusion is authorised are those set out in the authorised version of the protocol, or subsequent authorised amendments.
- ³⁰ Interactive Voice Response System: commonly used for randomisation of treatment and controlling the shipment of stock of product.
- ³¹ On an application to the Competent Authority only, the applicant to the Competent Authority needs to sign.

³² On an application to the Ethics Committee only, the applicant to the Ethics Committee needs to sign.